Use of ranolazine in long-QT syndrome type 3.
Kaufman
Elizabeth S
ES
D000083:Acetanilides / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D004562:Electrocardiography / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008133:Long QT Syndrome / Q000188:drug therapy* / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009124:Muscle Proteins / Q000235:genetics*; D062554:NAV1.5 Voltage-Gated Sodium Channel; D010879:Piperazines / Q000008:administration & dosage*; D000069458:Ranolazine; D012964:Sodium / Q000378:metabolism*; D015222:Sodium Channels / Q000235:genetics*; D016896:Treatment Outcome; D055815:Young Adult
D000083:Acetanilides; D004791:Enzyme Inhibitors; D009124:Muscle Proteins; D062554:NAV1.5 Voltage-Gated Sodium Channel; D010879:Piperazines; C568320:SCN5A protein, human; D015222:Sodium Channels; D012964:Sodium; D000069458:Ranolazine